Stoke Therapeutics, Inc. (STOK) News
Follow Stoke Therapeutics, Inc. (STOK) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Weekly Recap: Zorevunersen 2028 approval goal and Edward Kaye retirement
Stoke Therapeutics, Inc. (NASDAQ:STOK) said its antisense therapy zorevunersen aims to boost NaV1.1 in brain cells for a disease—modifying Dravet syndrome treatment with approval targeted around early 2028, as director E
NEWS | Sep 28, 2026, 11:06 AM UTC
L
Stoke Therapeutics names Alexander (Bo) Cumbo to board after Dr. Edward Kaye resignation
Stoke Therapeutics appointed Alexander (Bo) Cumbo to its Board as a Class III director, effective September 23, 2026, following the resignation of Edward M. Kaye, M.D.Original SEC Filing: Stoke Therapeutics, Inc. [ STOK
REGULATION | Sep 25, 2026, 08:15 PM UTC
L
Stoke Therapeutics, Inc. (STOK) Adds Bo Cumbo to Board
Stoke Therapeutics appointed Bo Cumbo to its Board of Directors as Edward Kaye, M.D., retires from the Board and will advise during the transition. The move adds commercial expertise as Stoke advances zorevunersen toward
REGULATION | Sep 23, 2026, 08:01 PM UTC
L
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in
REGULATION | Sep 23, 2026, 08:01 PM UTC
M
STOK Phase III Dravet and sustained seizure reduction support milestones
STOK says a phase III Dravet syndrome readout is expected within 12 months and progress continues in ADOA trials. Zorevunersen reports sustained 75% seizure reduction plus functional gains, with OLE data supporting long-
EQUITY | Sep 09, 2026, 06:35 PM UTC
M
STOK Phase III Dravet therapy reports durable 75%+ seizure reduction
Long-term data for a Phase III Dravet syndrome therapy show sustained 75%+ seizure reduction and functional gains. The pivotal EMPEROR trial is fully enrolled, with endpoints spanning seizures and cognitive improvements.
EQUITY | Sep 09, 2026, 06:08 PM UTC
L
Stoke and Biogen present long-term Zorevunersen data at EEC
Stoke Therapeutics and Biogen announced presentations of long-term clinical data supporting the disease-modifying potential of Zorevunersen, an investigational medicine for Dravet syndrome, at the 16th European Epilepsy
GEOPOLITICS | Sep 03, 2026, 11:30 PM UTC
L
Stoke Therapeutics to present at Cantor Global Healthcare Conference
Stoke Therapeutics, Inc. (STOK) said it will present at the Cantor Global Healthcare Conference.
EQUITY | Sep 02, 2026, 12:00 PM UTC
L
Stoke and Biogen to present Zorevunersen clinical data at EEC
Stoke Therapeutics and Biogen announced presentations of clinical data from studies of Zorevunersen, an investigational medicine for Dravet syndrome, at the 16th European Epilepsy Congress (EEC) in September.
GEOPOLITICS | Sep 01, 2026, 11:30 AM UTC
L
STOK initiated Overweight with $40.00 price target at JPMorgan
Hammerstone MarketTalk reports that JPMorgan initiated coverage of STOK with an Overweight rating and a $40.00 price target.
EQUITY | Aug 21, 2026, 11:58 AM UTC
L
Stoke Therapeutics Completes Enrollment Of 162 Patients Into Phase 3 EMPEROR Study Of Zorevunersen; Co Plans To Initiate Rolling NDA Submiss
Company plans to initiate a rolling U.S. NDA submission to the FDA in the first quarter of 2027— —Phase 3 data readout anticipated in the third quarter of 2027 to complete the rolling U.S. NDA submission in the second ha
REGULATION | Jun 30, 2026, 12:10 PM UTC